Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.6.5, indicating an updated site deployment. The previous Revision: v3.6.4 label has been superseded.
    Difference
    0.1%
    Check dated 2026-08-09T00:34:52.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    Removed the reference to the 2012 NEJM article Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. This background citation supported contextual information but is not part of the study's design, results, or eligibility details.
    Difference
    0.1%
    Check dated 2026-08-01T22:55:40.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The page shows a new revision tag v3.6.4 replacing the previous v3.6.3, indicating a minor patch or update to the page or system without visible content changes.
    Difference
    0.1%
    Check dated 2026-07-25T16:59:28.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page’s revision indicator was updated to v3.6.3, indicating a minor site update. This does not modify the study details or related data.
    Difference
    0.1%
    Check dated 2026-07-04T04:25:38.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    A classic NEJM trial reference on preoperative chemotherapy plus surgery for NSCLC was added, and the site revision tag was updated from v3.6.0 to v3.6.2.
    Difference
    0.1%
    Check dated 2026-06-27T03:05:41.000Z thumbnail image
  8. Check
    65 days ago
    Change Detected
    Summary
    Adds a literature citation for pembrolizumab in non-small-cell lung cancer (N Engl J Med. 2015;372:2018-2028) to provide background context for the drug's use in NSCLC.
    Difference
    0.1%
    Check dated 2026-06-19T22:09:26.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.